Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) generates a steady flow of news across Innovative Medicine and MedTech, reflecting its role in pharmaceutical preparation manufacturing and medical technologies. On this news page, readers can follow company announcements on clinical trial results, regulatory milestones, strategic transactions, manufacturing investments and corporate actions.
Recent oncology news includes positive topline data from the Phase 3 MajesTEC-9 study of TECVAYLI (teclistamab-cqyv) monotherapy in relapsed or refractory multiple myeloma, where Johnson & Johnson reported a substantial reduction in the risk of disease progression or death versus standard of care in a population predominantly refractory to anti-CD38 therapy and lenalidomide. The company has also shared longer-term results from the OrigAMI-1 study of RYBREVANT (amivantamab-vmjw) plus chemotherapy in metastatic colorectal cancer, supporting further Phase 3 evaluation of amivantamab-based regimens in first- and second-line settings.
In neuroscience and mental health, Johnson & Johnson has highlighted new data on CAPLYTA (lumateperone), SPRAVATO (esketamine) and the investigational agent seltorexant at major scientific meetings, including analyses focused on remission in major depressive disorder, treatment-resistant depression and sleep-related symptoms. The company has also announced positive Phase 2b results for nipocalimab in systemic lupus erythematosus and plans to initiate a Phase 3 program, underscoring its activity in autoantibody-driven diseases.
MedTech news covers developments such as the FDA submission of the OTTAVA robotic surgical system for De Novo classification, supported by an IDE study in gastric bypass procedures, and an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for chronic subdural hematoma. Corporate and financial updates, including quarterly dividend declarations, U.S. manufacturing investments and government agreements to improve access to medicines, also appear in Johnson & Johnson’s news flow. Investors, clinicians and observers can use this page to monitor how Johnson & Johnson’s clinical, regulatory and strategic decisions evolve over time.
Johnson & Johnson (NYSE: JNJ) announced promising data supporting the use of its COVID-19 vaccine as a booster for individuals previously vaccinated with its single-shot vaccine. Interim findings show that a booster dose significantly increases spike-binding antibodies by nine-fold compared to 28 days post-primary vaccination. The company is working with health authorities to discuss potential booster strategies. These results follow earlier Phase 1/2a studies demonstrating strong antibody responses lasting eight months post-vaccination.
Ovarian cancer victims are seeking a court order to prevent Johnson & Johnson (NYSE:JNJ) from moving its $500 billion assets to a subsidiary and declaring bankruptcy. This tactic, referred to as the "Texas Two-Step," aims to shield J&J from over $17 billion in liabilities linked to talc-cancer lawsuits.The plaintiffs argue that this move constitutes fraudulent conveyance, potentially halting over 34,000 claims. A trial in Missouri is scheduled for September 7, raising concerns over the implications for personal injury claimants if J&J's plan proceeds.
On August 19, 2021, Johnson & Johnson (NYSE: JNJ) announced that Alex Gorsky will transition into the role of Executive Chairman while Joaquin Duato, currently Vice Chairman, will become CEO, effective January 3, 2022. Gorsky has led the company as CEO since 2012, overseeing a 60% increase in R&D investments, reaching $12 billion in 2020. He emphasized the company's strong performance across all segments. Duato expressed enthusiasm for leading the company, highlighting its unmatched healthcare platform. The Board acknowledged the effective succession planning that enabled this leadership transition.
On August 12, 2021, Johnson & Johnson (NYSE: JNJ) announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference scheduled for September 15, 2021. The company will be represented by Joseph J. Wolk, Executive Vice President and CFO, and Mathai Mammen, Global Head of Research & Development, during a session at 9:30 a.m. (Eastern Time). Investors can access the live webcast via the Johnson & Johnson website, with a replay available 48 hours post-event.
Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Consumer Staples Virtual Conference on September 10, 2021. The event will feature Thibaut Mongon, Executive Vice President Worldwide Chairman of Consumer Health, speaking at 9:20 a.m. (Eastern Time). Investors and other interested parties can access the webcast via the Johnson & Johnson website. A replay of the webcast will be available approximately 48 hours after the event.
On July 29, 2021, lawmakers proposed reforms to prevent companies like Johnson & Johnson (JNJ) from using bankruptcy to evade liabilities related to talc products linked to ovarian cancer. The Nondebtor Release Prohibition Act aims to close loopholes such as non-consensual third-party releases and the Texas Two-Step strategy. JNJ has a market cap exceeding $400 billion and reported a 27% year-over-year sales increase to $23.31 billion, upgrading its annual forecast to $94.6 billion. Advocacy groups highlight the ethical implications of JNJ's potential bankruptcy strategy, stressing the need for corporate accountability.
Johnson & Johnson (NYSE: JNJ) will participate in the Virtual Wells Fargo Healthcare Conference on September 10, 2021. Joaquin Duato, Vice Chairman of the Executive Committee, is set to represent the company in a session starting at 10:00 a.m. Eastern Time. Interested investors can access the live webcast via the Johnson & Johnson website. A replay of the webcast will be available approximately 48 hours after the event.
Johnson & Johnson (NYSE: JNJ) reported impressive Q2 results with sales of $23.3 billion, up 27.1% year-over-year. Net earnings surged 73.1% to $6.3 billion, resulting in a diluted EPS of $2.35, a 72.8% increase. Key growth drivers included a 62.7% rise in Medical Devices sales, bolstered by market recovery from COVID-19, and a 17.2% increase in Pharmaceuticals, highlighted by strong performances from STELARA and DARZALEX. The Consumer Health segment also contributed with a 13.3% growth, driven by skin health products. JNJ emphasized ongoing innovations and external regulatory approvals.
Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.06 per share for the third quarter of 2021. This dividend is set to be paid on September 7, 2021, to shareholders on record by August 24, 2021. The ex-dividend date is August 23, 2021. Johnson & Johnson continues its commitment to shareholder returns while focusing on improving health access and affordability globally.
Attorneys representing women diagnosed with ovarian cancer linked to Johnson & Johnson's (NYSE: JNJ) talc products are condemning potential bankruptcy plans aimed at limiting the company's liability. Reports suggest J&J, with a market cap of $443 billion, may exploit bankruptcy to mitigate financial responsibilities from ongoing lawsuits. Lawyers highlight a history of dangerous practices, including the company's failure to replace talc with safer alternatives. A previous $2.1 billion judgment against J&J reflects significant negligence. Critics argue bankruptcy filings would deny victims justice.